Dr. Lal PathLabs Ltd. announced its financial results for the fourth quarter and full fiscal year 2026. The company reported a revenue of ₹703 crore for Q4 FY26, marking a 16.6% increase compared to the same period last year. For the full fiscal year 2026, revenue stood at ₹2,763 crore, a growth of 12.2% over FY25. This performance was primarily driven by an increase in sample volumes, which grew by 12.9% in Q4 and 10.4% in FY26. The company also highlighted the successful hosting of Medllumina 2026, an international medical conference focused on advanced diagnostics. Operationally, Dr. Lal PathLabs expanded its network by adding 14 new labs and over 1,100 collection centers during the year. The preventive healthcare brand, Swasthfit, contributed 27% to the total revenue in FY26. The company also launched Sovaaka, an AI-powered precision health screening service. Financially, EBITDA for Q4 FY26 was ₹187 crore (26.6% margin), and for the full year, it was ₹752 crore (27.2% margin). Excluding exceptional items, the adjusted EBITDA margin for FY26 was 28.3%, with a PAT margin of 19.3%. The company maintained a strong balance sheet with net cash and equivalents of ₹1,526 crore. The Board of Directors approved a final dividend of 40% (₹4 per share), bringing the total dividend for the year to ₹20.5 per share (280% after a 1:1 bonus adjustment). Dr. Lal PathLabs expects to sustain early to mid-teens revenue growth in FY27, with a planned capex of ₹100-₹120 crore for the next year, which includes investments in new labs and potentially 1-2 radiology centers.
